期刊
NEUROTHERAPEUTICS
卷 10, 期 1, 页码 2-18出版社
SPRINGER
DOI: 10.1007/s13311-012-0163-4
关键词
Interferon beta; Glatiramer acetate; Multiple sclerosis therapeutics; Review; History
资金
- National MS Society
- Acorda Therapeutics, Inc.
- Biogen Idec
- Novartis Pharmaceuticals Corp
- Teva Neuroscience, Inc.
- Genzyme
- Sanofi
- Celgene
- NIH
- NMSS Consulting Agreements/Advisory Boards/DSMB: Bayer HealthCare Pharmaceuticals
- EMD Serono, Inc
- Novartis
- Pfizer
- Teva Neuroscience
- Actelion
- Sanofi-Aventis
- Acorda
- Questcor
- Roche
- Genentech
- Johnson Johnson
- Revalesio
- Coronado Bioscience, Genzyme, MedImmune
- Bristol-Myers Squibb
Interferon beta and glatiramer acetate have been mainstays of treatment in relapsingremitting multiple sclerosis for two decades. Remarkable advances in our understanding of immune function and dysfunction as well as increasingly sophisticated clinical trial design have stemmed from efforts to better understand these drugs. In this chapter, we review the history of their development and elaborate on known and theorized mechanisms of action. We describe the pivotal clinical trials that have led to their widespread use. We evaluate the clinical use of the drugs including tolerability, side effects, and efficacy measures. Finally, we look to the future of interferon beta and glatiramer acetate in the context of an ever growing armamentarium of treatments for relapsing remitting multiple sclerosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据